EUVIMEDEUVIMED entdecken
Crossref

Nonsynonymous mutations in VEGF receptor binding domain alter the efficacy of bevacizumab treatment

Ashif Ahamed iD, Arijit Samanta iD, Syed Sahajada Mahafujul Alam iD, Showkat Ahmad Mir iD, Zarnain Jamil iD, Safdar Ali iD, Mehboob Hoque iD

Journal of Cellular Biochemistry · 2024

DOI: 10.1002/jcb.30515 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular Biochemistry, 2024. Verfasst von Ashif Ahamed und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Zoology, Netaji Subhas Open University, West Bengal, India. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor A, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vascular endothelial growth factor (VEGF) mediated angiogenesis is crucial for tumor progression. Isoforms of VEGF bind to different VEGF receptors (VEGFRs) to initiate angiogenesis specific cellular signaling. Inhibitors that target both the receptors and ligands are in clinical use to impede angiogenesis. Bevacizumab, a monoclonal antibody (mAb) approved by the Food and Drug Administration (FDA), binds in the VEGF receptor binding domain (RBD) of all soluble isoforms of VEGF and inhibits the VEGF‐VEGFR interaction. Bevacizumab is also used in combination with other chemotherapeutic agents for a better therapeutic outcome. Understanding the intricate polymorphic character of VEGFA gene and the influence of missense or nonsynonymous mutations in the form of nonsynonymous polymorphisms (nsSNPs) on RBD of VEGF may aid in increasing the efficacy of this drug. This study has identified 18 potential nsSNPs in VEGFA gene that affect the VEGF RBD structure and alter its binding pattern to bevacizumab. The mutated RBDs, modeled using trRosetta, in addition to the changed pattern of secondary structure, post translational modification and stability compared to the wild type, have shown contrasting binding affinity and molecular interaction pattern with bevacizumab. Molecular docking analysis by ClusPro and visualization using PyMol and PDBsum tools have detected 17 nsSNPs with decreased binding affinity to bevacizumab and therefore may impact the treatment efficacy. Whereas VEGF RBD expressed due to rs1267535717 (R229H) nsSNP of VEGFA has increased affinity to the mAb. This study suggests that genetic characterization of VEGFA before bevacizumab mediated cancer treatment is essential in predicting the appropriate efficacy of the drug, as the treatment efficiency may vary at individual level.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor AAntibodies, Monoclonal, HumanizedBevacizumabMolecular Docking SimulationAntibodies, MonoclonalReceptors, Vascular Endothelial Growth FactorProtein IsoformsMutationAngiogenesis Inhibitors

Stichwörter der Autor:innen

angiogenesis inhibitorsbevacizumabmolecular dockingmutationtumorvascular endothelial growth factors

Substanzen

BevacizumabVascular Endothelial Growth Factor AAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalReceptors, Vascular Endothelial Growth FactorProtein IsoformsAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Department of Zoology, Netaji Subhas Open University, West Bengal, India.
  • Applied Biochemistry Laboratory, Department of Biological Sciences, Aliah University, Kolkata, India.
  • School of Life Sciences, Sambalpur University, Jyoti Vihar, Odisha, India.
  • Clinical and Applied Genomics (CAG) Laboratory, Department of Biological Sciences, Aliah University, Kolkata, India.

ORCID-Profile: Ashif Ahamed, Arijit Samanta, Syed Sahajada Mahafujul Alam, Showkat Ahmad Mir, Zarnain Jamil, Safdar Ali, Mehboob Hoque

Zitieren

APA

Ahamed, A., Samanta, A., Alam, S. S. M., Mir, S. A., Jamil, Z., Ali, S., & Hoque, M. (2024). Nonsynonymous mutations in VEGF receptor binding domain alter the efficacy of bevacizumab treatment. Journal of Cellular Biochemistry. https://doi.org/10.1002/jcb.30515

Vancouver

Ahamed A, Samanta A, Alam SSM, Mir SA, Jamil Z, Ali S, et al. Nonsynonymous mutations in VEGF receptor binding domain alter the efficacy of bevacizumab treatment. Journal of Cellular Biochemistry. 2024. doi:10.1002/jcb.30515

BibTeX
@article{Ahamed2024,
  author = {Ahamed, Ashif and Samanta, Arijit and Alam, Syed Sahajada Mahafujul and Mir, Showkat Ahmad and Jamil, Zarnain and Ali, Safdar and Hoque, Mehboob},
  title = {Nonsynonymous mutations in VEGF receptor binding domain alter the efficacy of bevacizumab treatment},
  journal = {Journal of Cellular Biochemistry},
  year = {2024},
  doi = {10.1002/jcb.30515}
}
Kostenlos starten →